Total Synthesis of Ustiloxin D
ally unrelated rhizoxin and dolastatin 10,7 overlapping
somewhat with the vinca alkaloid binding site. As part
of the larger goal of understanding the mammalian
spindle assembly checkpoint, we are pursuing the syn-
theses of these natural products and structurally related
variants with the goal of dissecting the cell signaling
pathway by which the integrity of microtubules is
monitored.
Structure-activity relationships in microtubule depo-
lymerization assays indicate that the complex phomopsin
A tripeptide side chain is not essential since ustiloxin D
retains most of its antimitotic activity with a simple
glycine side chain (IC50 ) 2.4 vs 6.6 µM).8 Furthermore,
reduction and protection of the glycine acid does not even
change activity by an order of magnitude.8 Hydrogenation
of phomopsin A to octahydrophomopsin A9 had little effect
as well. Other structural differences include the opposite
stereochemistry at the C10 hydroxyl and chlorination of
the hydroxytyrosine arene. These elements are most
likely unnecessary features for microtubule depolymer-
ization. However, the 13-membered macrocyclic motif,
the hydroxytyrosine N-methylation, and the (R)-config-
uration of the C2 ether are preserved throughout each
family member.
FIGURE 1. Ustiloxin D retrosynthesis.
to add to and open this intermediate. Conditions that
weakly activated the acid resulted in no reaction. Though
we had anticipated these issues at the outset of this
strategy, given the myriad peptide coupling agents in
general use, it still appeared to be a tractable problem.
In particular, this failed reaction colored our retrosyn-
thetic analysis of ustiloxin D.
This family of molecules has attracted the interest of
many groups. Semisyntheses of analogues,8,10 pared down
ustiloxin model compounds,11 and the synthesis of the
chiral sulfoxide C12 substituent12 have been reported. Of
particular note, the Joullie´ group completed the first total
synthesis of ustiloxin D13 using a strategy by which the
C2 ether was assembled using nucleophilic aromatic
substitution and the C9/C10 amino alcohol was con-
structed by Sharpless’ asymmetric aminohydroxylation.
Our group has also recently completed an enantioselec-
tive synthesis.14
In pursuing a total synthesis of phomopsin B,15 we
synthesized the complete macrocycle and tripeptide side
chain with the goal of coupling these advanced interme-
diates in a highly convergent manner (Chart 1). Unfor-
tunately, the combination of the weak dehydroproline
nucleophile with the â-branched carbonyl and acylated
amine combined to block this coupling entirely. Condi-
tions that strongly activated the acid resulted in azlac-
tone formation and subsequent epimerization and race-
mization at C3. Furthermore, the side chain was not able
Results and Discussion
Retrosynthesis. During the development of our syn-
thetic strategy for ustiloxin D, our goal was to use
chemistry that would be compatible for application on
the more highly functionalized phomopsin system. Thus,
it was evident from our studies that the macrocycle
needed to be fully formed with the side chain already in
place as shown in Figure 1. We envisioned that such
closure could be brought about by a novel intramolecular
Staudinger ligation16 or a more conventional peptide
coupling strategy. This reduced the problem to linear
tetrapeptide 2 that could be formed from the dipeptide
precursor 3 by sequential coupling of the glycine side
chain and a valine-derived amino acid.
The problem of the tertiary aryl-alkyl ether had
previously been addressed using nucleophilic aromatic
substitution of a homochiral tertiary alcohol onto a
suitably activated arene moiety.13,15d This strategy placed
stringent demands on the electronics of the arene group,
requiring considerable functional group manipulation to
elaborate the natural product. To get around this prob-
lem, we took advantage of the high functional group
tolerance of the Pd asymmetric allylic alkylation.17 New
advances in this methodology led us to believe that this
disconnection might be particularly well-suited to deliver
the desired aryl-alkyl ether from phenol 4.
(7) Lin, Y.; Koiso, Y.; Kobayashi, H.; Hashimoto, Y.; Iwasaki, S.
Biochem. Pharmacol. 1995, 49, 1367-1372.
(8) Morisaki, N.; Mitsui, Y.; Yamashita, Y.; Koiso, Y.; Shirai, R.;
Hashimoto, Y.; Iwasaki, S. J. Antibiot. 1998, 51, 423-427.
(9) Lacey, E.; Edgar, J. A.; Culvenor, C. C. J. Biochem. Pharm. 1987,
36, 2133-2138.
(10) (a) Mutoh, R.; Shirai, R.; Koiso, Y.; Iwasaki, S. Heterocycles
1995, 41, 9-12. (b) Takahashi, M.; Shirai, R.; Koiso, Y.; Iwasaki, S.
Heterocycles 1998, 47, 163-166.
This phenol could in turn be realized by conducting
an aldol reaction between a glycine enolate equivalent
and a suitably protected 3,4-dihydroxybenzaldehyde 5.
Though most work toward these stereocenters has fo-
cused on enantioselective elaboration of an alkene
precursor,13,15c we chose to use an aldol approach for two
(11) La¨ıb, T.; Zhu, J. Synlett 2000, 1363-1365.
(12) Hutton, C. A.; White, J. M. Tetrahedron Lett. 1997, 38, 1643-
1646.
(13) (a) Park, H.; Cao, B.; Jouillie´, M. M. J. Org. Chem. 2001, 66,
7223-7226. (b) Cao, B.; Park, H.; Joullie´, M. M. J. Am. Chem. Soc.
2002, 124, 520-521.
(14) Tanaka, H.; Sawayama, A. M.; Wandless, T. J. J. Am. Chem.
Soc. 2003, 125, 6864-6865.
(15) (a) Stohlmeyer, M. M.; Tanaka, H.; Wandless, T. J. J. Am.
Chem. Soc. 1999, 121, 6100-6101. (b) Woiwode, T. F.; Rose, C.;
Wandless, T. J. J. Org. Chem. 1998, 63, 9594-9596. (c) Woiwode, T.
F.; Wandless, T. J. J. Org. Chem. 1999, 64, 7670-7674. (d) Woiwode,
T. F. Ph.D. Thesis, Stanford University, Stanford, California, 2000;
Chapters 2 and 3.
(16) (a) Nilsson, B. L.; Kiessling, L. L.; Raines, R. T. Org. Lett, 2001,
3, 9-12. (b) Nilsson, B. L.; Kiessling, L. L.; Raines, R. T. Org. Lett.
2000, 2, 1939-1941. (c) Soellner, M. B.; Nilsson, B. L.; Raines, R. T.
J. Org. Chem. 2002, 67, 4993-4996.
(17) Trost, B. M.; Toste, F. D. J. Am. Chem. Soc. 1999, 121, 4545-
4554.
J. Org. Chem, Vol. 69, No. 25, 2004 8811